On this two-day course you'll learn about all the steps in designing antibody therapeutics, from bioinformatics research to drug design and patient trials. The course is run by UCL's Division of Biosciences. Course content The following areas will be covered during this course: Understanding antibody sequence and structure, genetics and diversity Antibody applications, humanisation and fragments Bioinformatics for antibodies: how to search and analyse sequence and structure using powerful database software Designing therapeutics, including understanding the problems of using antibodies in vivo and the key methods used to circumvent them Manufacturing therapeutics Intellectual property: understanding basic intellectual property issues and relating these to humanising antibodies, including patent disputes Who this course is for The course is suitable for those involved in the design or manufacture of antibody-targeted therapies. This includes: scientists involved in researching, designing or manufacturing antibody therapies the medical community companies and industry involved in pharma research and manufacture postgraduate and professional researchers clinicians patent attorneys Prerequisites You'll need a science degree. You don't need previous experience of working with antibodies specifically. Structure and assessment You'll take part in bioinformatics workshops within small groups. There will also be a series of presentations and opportunities for discussion. There's no formal assessment. Schedule The first day is more introductory, while the second focuses on engineering for therapy. Day one will include: lectures on antibody structure, antibody applications and modelling antibodies by Dr Andrew Martin an interactive workshop on exploring and modelling antibodies a reception party with opportunities to network Day two will include: a lecture on antibody formats, humanisation and intellectual property by Dr Andrew Martin lectures on recombinant antibodies for cancer therapy by Professor Kerry Chester an interactive workshop on using the abYsis Antibody Analysis Platform a summing-up session with the chance to ask questions Learning outcomes On completing this course you should: be able to analyse antibody structure and sequence using the latest research and powerful software understand how bioinformatics is used in the design of therapeutics be able to use the latest developments at UCL to inform your own work have an understanding of intellectual property relating to this work be aware of the opportunities and challenges involved in antibody-targeted therapies Why you should attend By attending this course you'll: have an opportunity to discuss issues with experts in the field. You'll hear from leading researchers from Biosciences and the Cancer Institute at UCL explore the therapeutics from ideas to the clinic - a unique benchside-to-bedside overview have the opportunity to network with your industry peers have the chance to explore the UCL-created abYsis antibody bioinformatics system which allows analysis of antibody sequence and structure to help develop better therapeutics Employers: benefits of sending your staff on this course Staff attending this course will: discover the latest developments in analysing antibodies and methods of developing therapeutics from UCL have an opportunity to exchange knowledge and form partnerships discover new ideas to bring back to the workforce for increased productivity

Tel: 020 7679 2327

Website: ucl.ac.uk/short-courses/search-courses/antibodies-sequence-structure-and-designing-therapeutics

Sponsor: UCL